Search
Gyre Therapeutics Inc
GYREAdd to Watchlist
7.340USD
+0.820+12.58%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
670.67MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+12.58%
5 Days
+17.82%
1 Month
+32.01%
6 Months
+7.78%
Year to Date
+3.97%
1 Year
-5.90%
Key Figures
6.600Open
7.360High
101.75KVolume
LossP/E TTM
186.23P/E Dynamic
--Dividend TTM
0.11%Turnover Ratio
6.520Prev. Close
6.545Low
476.67KTurnover
55.47P/E Static
6.62P/B
0.00%Div Yield TTM
-2.54%ROA
9.92552wk High
0.82Volume Ratio
12.09MNet Profit
91.34MShares
-0.0701EPS TTM
1.85Beta
-7.51%ROE
5.67052wk Low
12.49%Amplitude
94.55%Gross Margin
670.67MMarket Cap
4.27Reward/Risk
3.41%Risk Rate
TradingKey Stock Score of Gyre Therapeutics Inc
Currency: USD Updated: 2026-07-02Key Insights
Gyre Therapeutics Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 81 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 18.67.In the medium term, the stock price is expected to remain stable.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Gyre Therapeutics Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Gyre Therapeutics Inc Highlights
StrengthsRisks
Gyre Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of F351 (Hydronidone) for the treatment of MASH-associated fibrosis in the United States. It is also advancing a diverse pipeline in the PRC through its indirect controlling interest in Gyre Pharmaceuticals, including ETUARY therapeutic expansions, F573, F528, and F230. F351 is a structural derivative of ETUARY. F573 is its clinical-stage product candidate for the treatment of acute/acute-on-chronic liver failure (ALF/ACLF) in Phase 2 clinical trials in the PRC. F528 is a preclinical-stage candidate targeting chronic obstructive pulmonary disease. F230 is a clinical-stage compound for the treatment of pulmonary arterial hypertension. It is focused on commercializing therapies for the treatment of pulmonary fibrosis through its two therapeutic products: ETUARY (pirfenidone) and nintedanib. It is also focused on commercializing the avatrombopag product.
Undervalued
The company’s latest PE is -104.68, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 4.60M shares, increasing 21.44% quarter-over-quarter.
Held by Bill Nygren | OAKMX
Star Investor Bill Nygren | OAKMX holds 2.62K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.05.
Analyst Rating
Based on
3
analysts
Buy
Current Rating
18.667
Target Price
+189.41%
Upside Space
Gyre Therapeutics Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Gyre Therapeutics Inc Info
Gyre Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of F351 (Hydronidone) for the treatment of MASH-associated fibrosis in the United States. It is also advancing a diverse pipeline in the PRC through its indirect controlling interest in Gyre Pharmaceuticals, including ETUARY therapeutic expansions, F573, F528, and F230. F351 is a structural derivative of ETUARY. F573 is its clinical-stage product candidate for the treatment of acute/acute-on-chronic liver failure (ALF/ACLF) in Phase 2 clinical trials in the PRC. F528 is a preclinical-stage candidate targeting chronic obstructive pulmonary disease. F230 is a clinical-stage compound for the treatment of pulmonary arterial hypertension. It is focused on commercializing therapies for the treatment of pulmonary fibrosis through its two therapeutic products: ETUARY (pirfenidone) and nintedanib. It is also focused on commercializing the avatrombopag product.
Ticker SymbolGYRE
CompanyGyre Therapeutics Inc
CEOZhang (Ping)
Websitehttps://www.gyretx.com/
Related Instruments
+1.62%
+3.50%
+3.96%
+3.72%
+3.31%
+6.14%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+2.95%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%Popular Instruments
52928.200
+85.700 (+0.16%)
29619.400
+308.000 (+1.05%)
7504.100
+32.600 (+0.44%)
14963.000
+160.000 (+1.08%)
69661.000
+1513.000 (+2.22%)
6380.500
+27.700 (+0.44%)
68.443
+0.099 (+0.14%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4178.390
+56.480 (+1.37%)
FAQs
What is the current price of Gyre Therapeutics Inc (GYRE)?
The current price of Gyre Therapeutics Inc (GYRE) is 7.34.
What is the symbol of Gyre Therapeutics Inc?
The ticker symbol of Gyre Therapeutics Inc is GYRE.
What is the 52-week high of Gyre Therapeutics Inc?
The 52-week high of Gyre Therapeutics Inc is 9.93.
What is the 52-week low of Gyre Therapeutics Inc?
The 52-week low of Gyre Therapeutics Inc is 5.67.
What is the market capitalization of Gyre Therapeutics Inc?
The market capitalization of Gyre Therapeutics Inc is 670.41M.
Is Gyre Therapeutics Inc (GYRE) currently rated as Buy, Hold, or Sell?
According to analysts, Gyre Therapeutics Inc (GYRE) has an overall rating of Buy, with a price target of 18.67.
What is the Earnings Per Share (EPS TTM) of Gyre Therapeutics Inc (GYRE)?
The Earnings Per Share (EPS TTM) of Gyre Therapeutics Inc (GYRE) is 0.06.